[go: up one dir, main page]

WO2010030936A3 - Atg14l et rubicon : nouveaux régulateurs de l'autophagie - Google Patents

Atg14l et rubicon : nouveaux régulateurs de l'autophagie Download PDF

Info

Publication number
WO2010030936A3
WO2010030936A3 PCT/US2009/056728 US2009056728W WO2010030936A3 WO 2010030936 A3 WO2010030936 A3 WO 2010030936A3 US 2009056728 W US2009056728 W US 2009056728W WO 2010030936 A3 WO2010030936 A3 WO 2010030936A3
Authority
WO
WIPO (PCT)
Prior art keywords
rubicon
activity
autophagic
pi3k
decrease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/056728
Other languages
English (en)
Other versions
WO2010030936A2 (fr
Inventor
Zhenyu Yue
Yun ZHONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Icahn School of Medicine at Mount Sinai
Original Assignee
Rockefeller University
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Mount Sinai School of Medicine filed Critical Rockefeller University
Publication of WO2010030936A2 publication Critical patent/WO2010030936A2/fr
Publication of WO2010030936A3 publication Critical patent/WO2010030936A3/fr
Priority to US13/046,428 priority Critical patent/US20120041175A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne la régulation à la hausse et à la baisse de l'autophagie cellulaire, pour traiter par exemple le cancer ou une maladie neurologique. L'invention résulte, en partie, de la découverte de deux nouvelles protéines, ATG14L (précédemment appelée « BISC ») et Rubicon (précédemment appelée « BIRC »), qui se lient au complexe autophagique phosphatidylinositol 3'-kinase de classe III (PI3K)/Vps34-Beclin 1. ATG14L et Rubicon régulent tous deux l'activité autophagique de manière opposée. ATG14L et Rubicon peuvent être utilisés, par exemple, pour augmenter/diminuer l'activité autophagique, pour augmenter/diminuer l'activité de kinase du complexe PI3K/Vps34, et de la sorte traiter des maladies et des troubles, tels que le cancer, des maladies neurodégénératives, un accident cérébrovasculaire, des maladies métaboliques, et d'autres maladies liés à l'âge. ATG14L peut augmenter l'activité autophagique et l'activité de kinase du complexe PI3K/Vps34; et Rubicon peut diminuer l'activité autophagique et l'activité de kinase du complexe PI3K/Vps34.
PCT/US2009/056728 2008-09-12 2009-09-11 Atg14l et rubicon : nouveaux régulateurs de l'autophagie Ceased WO2010030936A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/046,428 US20120041175A1 (en) 2008-09-12 2011-03-11 Novel autography regulators atg14l and rubicon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9672408P 2008-09-12 2008-09-12
US61/096,724 2008-09-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/046,428 Continuation US20120041175A1 (en) 2008-09-12 2011-03-11 Novel autography regulators atg14l and rubicon

Publications (2)

Publication Number Publication Date
WO2010030936A2 WO2010030936A2 (fr) 2010-03-18
WO2010030936A3 true WO2010030936A3 (fr) 2010-05-27

Family

ID=42005779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/056728 Ceased WO2010030936A2 (fr) 2008-09-12 2009-09-11 Atg14l et rubicon : nouveaux régulateurs de l'autophagie

Country Status (2)

Country Link
US (1) US20120041175A1 (fr)
WO (1) WO2010030936A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187802B2 (en) * 2008-11-19 2012-05-29 Rutgers, The State University Of New Jersey Cell lines useful for assessing modulation of autophagy
WO2011156637A1 (fr) * 2010-06-10 2011-12-15 University Of Southern California Peptides pphox et rubicon et procédés d'utilisation
EP2446886A1 (fr) 2010-10-29 2012-05-02 Fondazione Telethon Régulateurs d'autophagie et leurs utilisations dans le traitement de dystrophies musculaires dues à un défaut du collagène VI
US20130287792A1 (en) * 2012-04-27 2013-10-31 Jae Jung Compositions and methods to block mtb-mediated evasion
JP7182308B2 (ja) * 2018-07-27 2022-12-02 国立大学法人大阪大学 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
WO2020070235A1 (fr) * 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour restaurer ou améliorer des fonctions cognitives
US20220104468A1 (en) * 2019-01-22 2022-04-07 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
SG11202109290YA (en) * 2019-03-07 2021-09-29 Singapore Health Serv Pte Ltd Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites
US20250270619A1 (en) * 2021-01-18 2025-08-28 Life Technologies Corporation Compositions, kits and methods for direct amplification from crude biological samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020637A1 (en) * 2003-01-21 2007-01-25 Research Association For Biotechnology Full-length cDNA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020637A1 (en) * 2003-01-21 2007-01-25 Research Association For Biotechnology Full-length cDNA

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"UniProt K0831_MOUSE, Uniprot", GENOMENET; 2003, 1 March 2003 (2003-03-01), pages 1, 492, Retrieved from the Internet <URL:http://www.genome.jp/dbget-bin/www_bget?uniprot:K0831_MOUSE> [retrieved on 20100119] *
DATABASE EMBL [online] 18 December 2002 (2002-12-18), retrieved from http://www.ebi.ac.uk/cgi-bin/emblfetch?style=himl&id=AK029987&Submit=Go Database accession no. AK029967 *

Also Published As

Publication number Publication date
WO2010030936A2 (fr) 2010-03-18
US20120041175A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2010030936A3 (fr) Atg14l et rubicon : nouveaux régulateurs de l&#39;autophagie
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
UA91895C2 (en) Thiazole compounds and methods of use
WO2009011880A3 (fr) Modulateurs hétérocycliques de pkb
WO2007022506A3 (fr) Méthodes et préparations pour le traitement d&#39;une maladie neurologique
WO2009011871A3 (fr) Thiadiazoles modulateurs de l&#39;activité de pkb
EA201270480A1 (ru) Новые соединения
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
WO2008104953A3 (fr) Procédés et cibles d&#39;identification de composés permettant la régulation d&#39;une infection par rhinovirus
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
WO2012080729A3 (fr) Inhibiteurs de caséine kinase 1δ (ck1δ)
NO20084024L (no) Imidazolbaserte forbindelser, preparater omfattende slike, og anvendelse av slike
EP4585263A3 (fr) Thérapie génique pour troubles neurodégénératifs
WO2006058868A8 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
MX380755B (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
MX2009011360A (es) Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos.
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
WO2006044860A3 (fr) Composes de thiadiazole et leurs procedes d&#39;utilisation
EP2563794A4 (fr) Inhibiteurs de l&#39;activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MY149492A (en) Immunoglobulins directed against nogo
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren
UA88634C2 (en) Quaternized quinuclidine esters

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09813712

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09813712

Country of ref document: EP

Kind code of ref document: A2